TITLE:
Real-Life Results of a Cohort of Retroperitoneal Sarcomas (RPS): Management at Hassan II University Hospital in Fes
AUTHORS:
Medyouni Hajar, Chouef Jihane, Siyouri Oumaima, Chbihi Chaymae, Saoudi Amira, Amaadour Lamiae, Oualla Karima, Benbrahim Zineb, Arifi Samia, Mellas Nawfel
KEYWORDS:
Retroperitoneal Sarcomas (RPS), Multidisciplinary Approach, Chemotherapy, Metastatic Disease
JOURNAL NAME:
Open Access Library Journal,
Vol.11 No.4,
April
19,
2024
ABSTRACT: Retroperitoneal sarcomas (RPS) pose a challenge in treatment due to their rarity and complex nature. This retrospective study aimed to analyze the epidemiological, clinicopathological characteristics, and survival out-comes of RPS patients treated over an 11-year period. Seventeen patients diagnosed with RPS were included, with leiomyosarcoma being the most prevalent subtype. Surgical excision was the primary treatment modality, often complemented by radiotherapy and chemotherapy. The 5-year and 10-year overall survival rates were 56% and 46.9%, respectively, with a median progression-free survival of 10 months. Discussion highlights the importance of complete surgical resection and tumor grade as prognostic indicators. Local recurrence remains a significant concern despite advancements in treatment modalities. The role of radiotherapy in reducing local recurrence risk is acknowledged, particularly in the preoperative set-ting. For metastatic RPS, a multidisciplinary approach integrating surgery and systemic therapy is crucial. Patient selection for surgical interventions considers tumor biology, disease burden, and response to chemotherapy. Chemotherapy, primarily anthracycline-based, remains a cornerstone in managing unresectable or metastatic disease, with emerging agents showing promise in clinical trials. Overall, a tailored treatment approach emphasizing radical resection and adjuvant therapies offers the best chance for long-term survival in RPS patients.